News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
(USGovernment-News.Com, August 21, 2012 ) New York, NY -- All pending and future federal Pradaxa lawsuits have been consolidated to one central court, which will expedite litigation for bleeding victims. On August 8, 2012, the Judicial Panel on Multidistrict Litigation (JPML) entered an order centralizing these lawsuits in the Southern District of Illinois with the Honorable Judge David R. Herndon presiding. According to the Transfer Order, consolidation was appropriate because the cases “share common factual questions” stemming from allegations that plaintiffs suffered severe bleeding episodes or other serious injuries as a result of taking the blood thinner Pradaxa.
The Pradaxa lawsuits are alleging that the defendants, Boehringer Ingelheim, et al., did not properly warn doctors about the risks of Pradaxa, including the potential for life-threatening bleeding, and that there is no antidote for the drug’s anti-clotting effects. While all blood thinners pose a risk of serious and even fatal bleeding, the suits claim that because the drug has no reversal agent, surgeons, ER doctors and other medical professionals are left without an effective way to treat and stabilize patients who experience uncontrolled bleeding on the drug. The suits are calling Pradaxa’s lack of an antidote a dramatic departure from all other blood thinners.
In Dec. 2011, only 14 months after Pradaxa had been on the market, the FDA announced that it would be evaluating post-marketing reports of serious and sometimes fatal bleeding in Pradaxa users. The agency said it would be looking to determine whether these reports are occurring more frequently than should be expected. According to the agency, a large clinical trial revealed that when comparing Pradaxa and decades-old Coumadin, major bleeding events occurred at similar rates. Coumadin, however, has an antidote in Vitamin K, while no such reversal agent exists for Pradaxa, leaving users at risk for uncontrollable bleeding.
If you or a loved one suffered a serious bleeding event, such as a cerebral hemorrhage, while taking Pradaxa, it’s not too late to make a claim for monetary damages. To have your eligibility for a Pradaxa lawsuit evaluated, at no cost to you, please visit http://www.classaction.org/pradaxa.html and fill out the ‘Report a Complaint’ form on the right. The attorneys working with the site are offering this online consultation at no cost and with no obligation.
About Class Action.org
Class Action.org is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class Action.org keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit http://www.classaction.org today for a no cost, no obligation case evaluation and information about your consumer rights.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:
